KR20140030505A - 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 - Google Patents

이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 Download PDF

Info

Publication number
KR20140030505A
KR20140030505A KR1020120096036A KR20120096036A KR20140030505A KR 20140030505 A KR20140030505 A KR 20140030505A KR 1020120096036 A KR1020120096036 A KR 1020120096036A KR 20120096036 A KR20120096036 A KR 20120096036A KR 20140030505 A KR20140030505 A KR 20140030505A
Authority
KR
South Korea
Prior art keywords
hmg
coa reductase
reductase inhibitor
ibesaltan
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020120096036A
Other languages
English (en)
Korean (ko)
Inventor
김용일
권용진
박형민
이승엽
박재현
우종수
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140030505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to KR1020120096036A priority Critical patent/KR20140030505A/ko
Priority to ARP130103082A priority patent/AR092385A1/es
Priority to MX2015002591A priority patent/MX2015002591A/es
Priority to TW102131242A priority patent/TW201414511A/zh
Priority to CN201380045368.3A priority patent/CN104602678A/zh
Priority to JP2015529684A priority patent/JP2015526509A/ja
Priority to EP13834178.9A priority patent/EP2890371A4/en
Priority to RU2015111523A priority patent/RU2015111523A/ru
Priority to CA2882738A priority patent/CA2882738A1/en
Priority to SG11201500580QA priority patent/SG11201500580QA/en
Priority to PE2015000255A priority patent/PE20150402A1/es
Priority to BR112015004091A priority patent/BR112015004091A2/pt
Priority to PCT/KR2013/007841 priority patent/WO2014035190A1/en
Priority to US14/420,953 priority patent/US20150231085A1/en
Priority to IN1738DEN2015 priority patent/IN2015DN01738A/en
Priority to UY0001035000A priority patent/UY35000A/es
Priority to EA201590474A priority patent/EA201590474A1/ru
Priority to AU2013309688A priority patent/AU2013309688A1/en
Publication of KR20140030505A publication Critical patent/KR20140030505A/ko
Priority to CL2015000363A priority patent/CL2015000363A1/es
Priority to PH12015500395A priority patent/PH12015500395A1/en
Priority to IL237425A priority patent/IL237425A0/en
Priority to DO2015000042A priority patent/DOP2015000042A/es
Priority to NI201500028A priority patent/NI201500028A/es
Priority to CR20150124A priority patent/CR20150124A/es
Priority to CO15058341A priority patent/CO7350622A2/es
Priority to ECIEPI201510617A priority patent/ECSP15010617A/es
Priority to MA37953A priority patent/MA37953A1/fr
Priority to ZA2015/02157A priority patent/ZA201502157B/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020120096036A 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 Ceased KR20140030505A (ko)

Priority Applications (28)

Application Number Priority Date Filing Date Title
KR1020120096036A KR20140030505A (ko) 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
ARP130103082A AR092385A1 (es) 2012-08-31 2013-08-29 FORMULACION DE UNA CAPSULA FARMACEUTICA COMPUESTA QUE COMPRENDE IRBESARTAN E INHIBIDOR DE LA HMG-CoA REDUCTASA
AU2013309688A AU2013309688A1 (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and HMG-CoA reductase inhibitor
IN1738DEN2015 IN2015DN01738A (enExample) 2012-08-31 2013-08-30
UY0001035000A UY35000A (es) 2012-08-31 2013-08-30 ?formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa?.
CN201380045368.3A CN104602678A (zh) 2012-08-31 2013-08-30 包含厄贝沙坦和hmg-coa还原酶抑制剂的药物复合胶囊制剂
JP2015529684A JP2015526509A (ja) 2012-08-31 2013-08-30 イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤
EP13834178.9A EP2890371A4 (en) 2012-08-31 2013-08-30 CAPSULE FORMULATION FOR A PHARMACEUTICAL COMPOSITION WITH IRBESARTAN AND AN HMG COA REDUCTASE INHIBITOR
RU2015111523A RU2015111523A (ru) 2012-08-31 2013-08-30 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
CA2882738A CA2882738A1 (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
SG11201500580QA SG11201500580QA (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
PE2015000255A PE20150402A1 (es) 2012-08-31 2013-08-30 Formulacion de una capsula farmaceutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
BR112015004091A BR112015004091A2 (pt) 2012-08-31 2013-08-30 formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase
PCT/KR2013/007841 WO2014035190A1 (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
US14/420,953 US20150231085A1 (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
MX2015002591A MX2015002591A (es) 2012-08-31 2013-08-30 Formulacion de una capsula farmaceutica compuesta que comprende irbesartan e inhibidor de la hmg - coa reductasa.
TW102131242A TW201414511A (zh) 2012-08-31 2013-08-30 含有厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及ｈｍｇ－ｃｏａ還原酶抑制劑之藥學的複合膠囊調配物
EA201590474A EA201590474A1 (ru) 2012-08-31 2013-08-30 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
CL2015000363A CL2015000363A1 (es) 2012-08-31 2015-02-16 Una formulacion de una capsula farmaceutica compuesta que comprende 1) una unidad independiente comprendiendo irbesartan o una de sus sales y 2) una unidad independiente comprendiendo un inhibidor de la hmg-coa reductasa o una de sus sales y un aditivo alcalino, en donde dichas unidades independientes se separan unas de otras dentro de la capsula; y su metodo de preparacion.
PH12015500395A PH12015500395A1 (en) 2012-08-31 2015-02-24 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
IL237425A IL237425A0 (en) 2012-08-31 2015-02-25 Composite capsule pharmaceutical preparation containing irbesartan and HMG coa reductase inhibitor and methods for its production
DO2015000042A DOP2015000042A (es) 2012-08-31 2015-02-26 Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
NI201500028A NI201500028A (es) 2012-08-31 2015-02-27 Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa.
CR20150124A CR20150124A (es) 2012-08-31 2015-03-11 Formulación de una cápsula farmcéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
CO15058341A CO7350622A2 (es) 2012-08-31 2015-03-13 Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
ECIEPI201510617A ECSP15010617A (es) 2012-08-31 2015-03-20 Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invención
MA37953A MA37953A1 (fr) 2012-08-31 2015-03-27 Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase
ZA2015/02157A ZA201502157B (en) 2012-08-31 2015-03-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120096036A KR20140030505A (ko) 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020190076487A Division KR102042626B1 (ko) 2019-06-26 2019-06-26 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제

Publications (1)

Publication Number Publication Date
KR20140030505A true KR20140030505A (ko) 2014-03-12

Family

ID=50183919

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120096036A Ceased KR20140030505A (ko) 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제

Country Status (28)

Country Link
US (1) US20150231085A1 (enExample)
EP (1) EP2890371A4 (enExample)
JP (1) JP2015526509A (enExample)
KR (1) KR20140030505A (enExample)
CN (1) CN104602678A (enExample)
AR (1) AR092385A1 (enExample)
AU (1) AU2013309688A1 (enExample)
BR (1) BR112015004091A2 (enExample)
CA (1) CA2882738A1 (enExample)
CL (1) CL2015000363A1 (enExample)
CO (1) CO7350622A2 (enExample)
CR (1) CR20150124A (enExample)
DO (1) DOP2015000042A (enExample)
EA (1) EA201590474A1 (enExample)
EC (1) ECSP15010617A (enExample)
IL (1) IL237425A0 (enExample)
IN (1) IN2015DN01738A (enExample)
MA (1) MA37953A1 (enExample)
MX (1) MX2015002591A (enExample)
NI (1) NI201500028A (enExample)
PE (1) PE20150402A1 (enExample)
PH (1) PH12015500395A1 (enExample)
RU (1) RU2015111523A (enExample)
SG (1) SG11201500580QA (enExample)
TW (1) TW201414511A (enExample)
UY (1) UY35000A (enExample)
WO (1) WO2014035190A1 (enExample)
ZA (1) ZA201502157B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
EP3184103A1 (en) * 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
BR112019028235B1 (pt) * 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
CN110237070A (zh) * 2019-05-10 2019-09-17 辽宁大学 厄贝沙坦在制备降血脂药物中的应用
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
WO2009118359A2 (en) * 2008-03-28 2009-10-01 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
WO2009134076A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 방출성이 제어된 안지오텐신 - II - 수용체 차단제와 H M G - C o A 환원 효소 억제제의 복합제 조성물
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
US9056134B2 (en) * 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Also Published As

Publication number Publication date
BR112015004091A2 (pt) 2017-07-04
DOP2015000042A (es) 2015-04-30
RU2015111523A (ru) 2016-10-20
MA37953A1 (fr) 2017-01-31
ECSP15010617A (es) 2015-12-31
MX2015002591A (es) 2015-06-10
AU2013309688A1 (en) 2015-02-26
US20150231085A1 (en) 2015-08-20
SG11201500580QA (en) 2015-02-27
AR092385A1 (es) 2015-04-22
NI201500028A (es) 2017-01-04
IL237425A0 (en) 2015-04-30
UY35000A (es) 2014-03-31
PH12015500395A1 (en) 2015-04-27
EP2890371A4 (en) 2016-04-06
JP2015526509A (ja) 2015-09-10
CL2015000363A1 (es) 2015-06-05
TW201414511A (zh) 2014-04-16
PE20150402A1 (es) 2015-04-13
EP2890371A1 (en) 2015-07-08
CA2882738A1 (en) 2014-03-06
EA201590474A1 (ru) 2015-06-30
IN2015DN01738A (enExample) 2015-05-29
CO7350622A2 (es) 2015-08-10
CR20150124A (es) 2015-04-24
WO2014035190A1 (en) 2014-03-06
ZA201502157B (en) 2016-10-26
CN104602678A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
CA2703598C (en) Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
KR101290925B1 (ko) 코팅된 정제 제형 및 방법
EP2568972B1 (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
AU2017210661A1 (en) Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of SGLT
KR20150079454A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
US20080008752A1 (en) Pharmaceutical compositions of memantine
KR101502031B1 (ko) 약제학적 복합제제
KR20140030505A (ko) 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
WO2021074808A1 (en) Pharmaceutical composition comprising sacubitril and valsartan and process for preparation thereof
WO2003032954A1 (en) Stabilized pharmaceutical formulations containing amlodipine maleate
KR102042626B1 (ko) 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
EP4566591A1 (en) Solid pharmaceutical dosage form comprising ezetimibe and pitavastatin
HK40084344A (en) Pharmaceutical compositions
HK1200107A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
KR20110132171A (ko) 니아신 함유 복합 제어방출성 제제
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20120831

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170821

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20120831

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180913

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190328

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180913

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190328

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181102

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190603

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190429

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190328

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181102

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180913

PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20190626

Patent event code: PA01071R01D